Skip to main content
Equibles
ZYME logo

ZYME · Zymeworks Inc.

Track ZYME — free

Use ZYME with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ZYME

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$25.12 -0.64 (-2.48%) At close · Aug 14
Market Cap
$1.78B
Shares
70.96M

Zymeworks Inc. Earnings Call Transcripts

Every quarterly earnings call for Zymeworks Inc. (ZYME) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼40.1% $2.63M −$47.85M '22 Q3 22-11-08 · $402.49M $309.43M '22 Q4 23-03-07 ▲1756.9% $35.58M −$24.35M '23 Q1 23-05-08 ▲28.7% $7.00M −$51.15M '23 Q2 23-08-10 ▲527.4% $16.51M −$28.69M '23 Q3 23-11-07 ▼95.8% $16.93M −$14.48M '23 Q4 24-03-06 ▼71.8% $10.03M −$31.65M '24 Q1 24-05-02 ▲174.8% $19.24M −$37.69M '24 Q2 24-08-01 ▼3.1% $16.00M −$29.85M '24 Q3 24-10-31 ▲83.3% $31.03M −$23.51M '24 Q4 25-01-08 ▲170.3% $27.11M −$22.64M '25 Q1 25-05-08 ▲153.2% $48.73M $2.32M '25 Q2 25-08-07 ▲72.6% $27.61M −$19.60M '25 Q3 25-11-06 ▼91.9% $2.52M −$41.21M '25 Q4 26-03-02 ▼91.1% $2.41M −$44.16M '26 Q1 26-05-07 LATEST ▼90.6% $4.59M −$45.02M '26 Q2 26-08-06
Conference
Investor event
2026-09-15
H.C. Wainwright Annual Global Investment Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Morgan Stanley Healthcare Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
Wells Fargo Healthcare Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Zymeworks Inc. Q2 FY2026 Earnings Call
Revenue
$4.59M
▼ 90.6% YoY
Diluted EPS
$-0.62
▼ 2166.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Zymeworks Inc. Q1 FY2026 Earnings Call
Confident tone ADC pipeline and AACR data Zanidatamab regulatory milestones Royalty aggregation business model
Revenue
$2.41M
▼ 91.1% YoY
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-21
2026 Bloom Burton & Co. Healthcare Investor Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-02
Zymeworks Inc. Q4 FY2025 Earnings Call
Confident tone Zanidatumab GEA regulatory and commercial progress Royalty and milestone economics from collaborations ZW191 Phase I progress in GPC3-expressing tumors
Revenue
$2.52M*
▼ 91.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Zymeworks Inc. Q3 FY2025 Earnings Call
Confident tone ZW191 Phase I ADC (folate receptor alpha) ZW251 Phase I ADC (GPC3, hepatocellular carcinoma) DLL3 T-cell engager (preclinical/ZW171)
Revenue
$27.61M
▲ 72.6% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Zymeworks Inc. Q2 FY2025 Earnings Call
Confident tone Wholly-owned ADC pipeline (ZW171, ZW191, ZW251, ZW220) Timing and disclosure of ZW191 data Preclinical IL-4/IL-33 bispecific (ZW1528) for COPD
Revenue
$48.73M
▲ 153.2% YoY
Diluted EPS
$0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Zymeworks Inc. Q1 FY2025 Earnings Call
Positive tone Bispecific T-cell engager vs ADC strategy Pipeline and preclinical data Partnerships and milestones
Revenue
$27.11M
▲ 170.3% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-08
Zymeworks Inc. Q4 FY2024 Earnings Call
Positive tone Partnership milestones and revenue ADC programs (ZW251, ZW220, ZW191) Financial performance and operating expenses
Revenue
$31.03M*
▲ 83.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Zymeworks Inc. Q3 FY2024 Earnings Call
Positive tone Wholly owned pipeline progress (ZW171, ZW191, ZW220, ZW251) Zanidatamab (Zani) updates with Jazz Pharmaceuticals Partner programs and licensing revenue
Revenue
$16.00M
▼ 3.1% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Zymeworks Inc. Q2 FY2024 Earnings Call
Positive tone Wholly-owned pipeline advancement Zanidatamab regulatory progress Mesothelin T-cell engager safety and design (ZW171)
Revenue
$19.24M
▲ 174.8% YoY
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Zymeworks Inc. Q1 FY2024 Earnings Call
Confident tone Upcoming INDs and Phase 1 Studies Zanidatamab Partnership Progress TriTCE Trispecific Platform
Revenue
$10.03M
▼ 71.8% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Zymeworks Inc. Q4 FY2023 Earnings Call
Confident tone 5x5 early-stage pipeline Zanidatamab commercial outlook Partner execution (Jazz/BeiGene)
Revenue
$16.93M*
▼ 95.8% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zymeworks Inc. Q3 FY2023 Earnings Call
Revenue
$16.51M
▲ 527.4% YoY
Diluted EPS
$-0.41
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Zymeworks Inc. Q2 FY2023 Earnings Call
Revenue
$7.00M
▲ 28.7% YoY
Diluted EPS
$-0.76
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Zymeworks Inc. Q1 FY2023 Earnings Call
Revenue
$35.58M
▲ 1756.9% YoY
Diluted EPS
$-0.37
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Zymeworks Inc. Q4 FY2022 Earnings Call
Revenue
$402.49M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Zymeworks Inc. Q3 FY2022 Earnings Call
Revenue
$2.63M
▼ 40.1% YoY
Diluted EPS
$-0.72
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Zymeworks Inc. Q2 FY2022 Earnings Call
Revenue
$5.44M
Diluted EPS
$-0.97
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Zymeworks Inc. Q1 FY2022 Earnings Call
Revenue
$1.92M
Diluted EPS
$-1.19
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Zymeworks Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 1937653 CUSIP 98985Y108 13F (30d) 197 filings 196 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)